German researchers recently developed a new system that calculates the risk level of multiple myeloma patients based on patient’s overall health status and other diseases a patient has in addition to myeloma.

Their system, called the Freiburg Comorbidity Index, calculates a patient’s risk level by determining the presence of known risk factors, such as poor overall health and kidney or lung disease.

The researchers found that this index can be used independently to predict progression-free survival and overall survival in myeloma patients.

More importantly, they found that when the Freiburg Comorbidity Index …